Progressive multifocal leukoencephalopathy after natalizumab monotherapy

New England Journal of Medicine

Volumn 361, Issue 11, 2009, Pages 1081-1087

  Lindå, Hans ^a   Von Heijne, Anders ^a   Major, Eugene O ^b   Ryschkewitsch, Caroline ^b   Berg, Johan ^a   Olsson, Tomas ^a   Martin, Claes ^a  

^a DANDERYD HOSPITAL   (Sweden)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; IMMUNOMODULATING AGENT; METHYLPREDNISOLONE; MIRTAZAPINE; NATALIZUMAB; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID; CLINICAL FEATURE; CROHN DISEASE; DISEASE COURSE; DRUG CLEARANCE; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; JC VIRUS; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

EID: 70149111495     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0810316     Document Type: Article

References (22)

1. Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 2004;17:365-370 (Pubitemid 38720991)
2. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-747 (Pubitemid 43673151)
3. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23. (Pubitemid 36026342)
4. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910. (Pubitemid 43313657)
5. Yang XD, Michie SA, Tisch R, Karin N, Steinman L, McDevitt HO. A predominant role of integrin alpha 4 in the spontaneous development of autoimmune diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994;91:12604-12608
6. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-1925 (Pubitemid 41565956)
7. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-381 (Pubitemid 41132342)
8. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374 (Pubitemid 41132341)
9. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-933 (Pubitemid 43313659)
10. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368 (Pubitemid 41132340)
11. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009;72:402-409
12. Ryschkewitsch C, Jensen P, Hou J, Fahle G, Fischer S, Major EO. Comparison of PCR-Southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods 2004;121:217-221 (Pubitemid 39295712)
13. Landry ML, Eld T, Bannykh S, Major EO. False negative PCR despite high levels of JC virus DNA in spinal fluid: implications for diagnostic testing. J Clin Virol 2008;43:247-249
14. Aksamit AJ. Progressive multifocal leukoencephalopathy. Curr Treat Options Neurol 2008;10:178-185
15. Venkataramana A, Pardo CA, McArthur JC, et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 2006;67:383-388 (Pubitemid 44214957)
16. Hemmer B, Frohmann E, Hartung HP, Stüve O. Central nervous system infections - a potential complication of systemic immunotherapy. Curr Opin Neurol 2006;19:271-276 (Pubitemid 43804682)
17. Martin SI, Marty FM, Fuimara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43:16-24.
18. Pelosini M, Focosi D, Rita F, et al. Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of the literature. Ann Hematol 2008;87:405-412
19. Iacobaeus E, Ryschkewitsch C, Gravell M, et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler 2009;15:28-35.
20. Falcó V, Olmo M, del Saz SV, et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr 2008;49:26-31.
21. Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Luca A. Reduced rate of diagnostic detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005;43:4175-4177 (Pubitemid 41129718)
22. Hamilton RS, Gravell M, Major EO. Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol 2000;38:105-109 (Pubitemid 30043273)